Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 11Gastrointestinal 2CNS 2Head & Neck 1Endocrine 1

Conditions

Tongue Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Parathyroid Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Eating 5Standard of Care 4Radiofrequency Ablation 4Exercise 4Endoscopic Mucosal Resection 4Surgical Procedures, Operative 3Radiosurgery 3Adrenalectomy 3lutetium Lu 177 dotatate 2Yoga 2Saline Solution 2Robotic Surgical Procedures 2Resistance Training 2Proton Therapy 2Propofol 2Palliative Care 2Octreotide 2Magnetic Resonance Imaging 2Lutetium-177 2Liquid Biopsy 2Interviews as Topic 2Hydrocortisone 2Diet, Mediterranean 2Diet 2Desflurane 2Data Collection 2Conversion to Open Surgery 2Control Groups 2Calcium 23-Iodobenzylguanidine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Gefitinib × Endocrine × Clear all
NCT00068497 2013-01-14

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase NA Completed
40 enrolled
CNSEndocrineHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Parathyroid Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Tongue Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡